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PROMPT DETECTION OF L-ASPARAGINASE INACTIVATION IS CRUCIAL TO OPTIMIZE TREATMENT 
EFFICACY ALSO IN AGGRESSIVE LYMPHOMAS 
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To the Editor,  
 
The use of L-asparaginase (L-ASP) has significantly improved the prognosis of acute 
lymphoblastic leukemia (ALL), especially in pediatric and adolescents-young adult patients.
1 
In L-ASP-containing protocols designed for the treatment of ALL, therapeutic drug monitoring of 
asparaginase activity is recommended, in order to achieve and maintain appropriate enzymatic 
exposure, which is required for a complete and protracted depletion of L-asparagine (L-ASN) in 
serum.
2,3 
Serum enzymatic activity of 100 IU/L is generally accepted as the level necessary to 
obtain the therapeutic depletion of L-ASN .
2,3
 
However, the main factor limiting L-ASP activity is the formation of neutralizing antibodies 
leading to the inactivation of the enzyme and consequent reduction of its activity.
4 
Correlations 
between hypersensitivity manifestations and drug inactivation or increased drug clearance 
have been reported. Nevertheless, patients often experience the so called “silent inactivation” 
(i.e. the developing of neutralizing anti-asparaginase antibodies in the absence of evident 
clinical symptoms, that leads to low or missing enzymatic activity in serum after L-ASP 
administration).
 
The detection of silent inactivation by testing serum asparaginase activity is 
therefore essential to verify the achievement of the therapeutic depletion of L-ASN.
3,4
 
The efficacy of L-ASP-containing regimens has been recently reported also in peripheral T-Cell 
lymphomas
5,6 
but no information is currently available on the clinical relevance of silent 
inactivation in this subset of patients. 
We report here a case of a 30-years-old man with Hepatosplenic γδ T-Cell Lymphoma (HSL), a 
rare form of peripheral T-Cell lymphoma with a dismal prognosis. The patient was admitted to 
our division for persistent fever, intense asthenia and night sweats. Laboratory analysis showed 
leukocytosis (20000 WBC/mmc), severe anemia and thrombocytopenia, and disseminated 
intravascular coagulation. Morphological examination of peripheral blood smears showed the 




































































presence of atypical large agranular vacuolated cells. Flow-cytometry revealed a clonal γδ T-Cell 
population with the following phenotype; CD3+, CD4-, CD8-, TCR γδ+. Bone marrow core biopsy 
confirmed the diagnosis of HSL. An informed consent allowing collection and reporting of 




 which includes steroid (dexamethasone), methotrexate, 
ifosfamide, etoposide and L-ASP was started. The Escherichia-coli derived L-ASP native 
formulation was administered at the 6000 U/sqm dose intravenously every 48 hours from day 
8, for 7 doses, as per SMILE protocol. After the first course of chemotherapy a partial remission 
was achieved, with a 75% reduction in bone marrow lymphoid infiltration. The response 
however proved to be transient as a second bone marrow biopsy performed after the second 
course of therapy showed an increase of neoplastic infiltration. Furthermore no alterations of 
coagulation tests, that are typically associated with L-ASP therapy, had been observed. 
Following our experience with ALL patients we checked serum asparaginase activity, through 
the MAAT™ enzymatic test (kindly provided by Medac GmbH, Germany)
8 
and documented 
inactivation of the enzyme, being detectable only a level of 32 IU/L, 48 hour after the 6
th
dose of 
E. coli L-ASP. Both clinical and laboratory findings prompted us to substitute E. coli L-ASP with 
the E. chrysanthemi-derived enzyme.
9 
Following this change, a satisfactory serum asparaginase 
level of 120 IU/L at 48 hours after the 4
th 
dose of E. chrysanthemi L-ASP was obtained. In 
addition, as proof of concept, we checked by HPLC mass spectrometry the presence of the L-
ASN in the serum that resulted undetectable. Most importantly, after the drug shift, bone 
marrow biopsy showed a recovery of the response, with a maximum reduction of 92% of 
neoplastic infiltration after the fifth cycle. Patient then received an haploidentical allogeneic 
bone marrow transplantation after the sixth cycle.
 




































































It is known from the pediatric ALL experience that the sub-optimal or the complete inactivation, 
of the L-ASP serum activity is correlated with a worse prognosis.
3,9
 Few data are however 
available on the clinical utility of enzymatic activity monitoring in adult ALL patients and, as far 
as we know, the monitoring of L-ASP activity has never been routinely performed in patients 
affected by mature T-Cell lymphomas. 
Although no allergic clinical signs were present, the loss of clinical response together with the 
lack of toxicity suggested us to check the serum asparaginase activity which allowed us to 
document a silent inactivation. Since the shift to the E. chrysanthemi-derived enzyme led to a 
recovery and a further imp ovement of clinical response, we may conclude that this positive 
effect was due to the recovered activity of L-ASP, which was confirmed by subsequent 
determinations. This observation is consistent with the clinical management of ALL patients, 
where the detection of L. ASP inactivation leads to the substitution with E. chrysanthemi 
derived L-ASP, which is usually able to restore the effectiveness of the asparaginase treatment.
9
 
In a recent review focusing on the utilization of L-ASP containing regimens in T/NK neoplasms, 
routine L-ASP activity monitoring is suggested for future trials.
10
 
The detection of silent inactivation in our adult HSL patient confirms the clinical utility of 
planning a regular assessment of serum L-ASP activity, regardless of the diagnosis and the 
presence of overt allergic reactions, in order to maximize its therapeutic efficacy, eventually 
through an early shift to an alternative drug preparation. 
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